However, serum IL-12 and IFN-γ levels were significantly increased in both GC and CRC patients, indicating that DC/CIK therapy may specifically promote a Th1 immune response to mediate tumor killing effect of DC/CIK therapy. Here, IFNG is linked to colorectal carcinoma.